Irlab's shares plummet 60% after Ipsen-partnered Parkinson's drug flunks phase 2 trial

Irlab Therapeutics' stock has cratered after the Swedish biotech reported that its Ipsen-partnered Parkinson’s therapy failed to reduce involuntary body movements in a phase 2b trial.